A global Oncology Pharmaceutical Company Founded in China
Committed to Enhancing and Improving Survival of Tumor Patients through Personalized Tumor Immunotherapy
It is one of those pioneers promoting the clinical approval of tumor immunotherapy with the help of precision medicine and combined immunotherapy
A marketing team covering 4,000 oncologists has been established for companion diagnostics and testing services. The marketing network will see a fivefold increase in the next two years to boost the sales of drugs
As a leading tumor precision immune drugs development company in China, it has three global-market-oriented novel drug projects for tumor immunology, two of which are about to launch phase II and phase III key clinical trials worldwide
It is one of the few novel drug development companies in China that promotes innovative drugs into the later stages of global MRCT clinical trials
The tumor combination immunotherapy strategy for integrating global innovative drug resources centered on anti-PD-L1 antibody boosts multiple combination therapies into global clinical trials. In the next year, 7 combination therapies will enter global clinical trials in multiple indications.
Key clinical trial data of the marker-driven PD-L1 antibody guided by precision medicine will be published within 12 months.
It is expected that two first-line tumor immune drugs, which are being tested in key phase II and phase III clinical trials in China and the United States, will complete NDA submissions for no less than 5 indications in China and the United States in 2019 and 2020, respectively
Time is the Mark that the Pioneer Goes Forward, and the Witness that the Striver Builds a Dream
Make Breakthroughs and Innovate More
Maximize 3DMed’s Value through Patient-centered Preventive Treatment of Disease
Sun Yat-sen University Cancer Center
(the largest cancer center in southern China for cancer care, education and research)
The Sixth Affiliated Hospital of Sun Yat-Sen University
(one of the most influential gastrointestinal hospitals in China and a national key clinical hospital)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
(a large clinical center in southern China for single disease of breast tumor)
Chongqing Cancer Hospital
(chairman of the Committee of Gynecological Oncology, China Anti-Cancer Association)
3DMed Medical Laboratory served more than 20,000 tumor patients
About 50% of these patients are recommended with potentially beneficial drugs
|Project No||Mechanism||Right||PrelND||IND||Dose Escalation||Dose Expansion||Registered Trail||Difference|
1st subcutaneous PD-L1 in the world, greatly increased convenience and reduced treatment cost
Targeting Specific signal pathway, potential combination of immunotherapy
Targeting Specific organ, reduce systemic toxicity
Beginning of proliferation
BRCA 1/2 gene, risk of breast and ovarian cancer
17 hereditary colorectal cancer related genes covered
44 genes covering BRCAness and HRD-related genes, covering all major hereditary tumor-related genes (recommended by NCCN)
Ground-breaking exosome detection technology for early diagnosis of ovarian with a sensitivity up to 95%
The most complete and accurate companion diagnostic product for immunotherapy, fully covering the immunotherapy, targeted therapy, chemotherapy and prognosis
Fully excavation of mutagenesis information of tumor patients to assist clinicians in developing personalized treatment plans
With the innovative blood ctDNA detection technology, the molecular barcode is added via a self-developed ctDNA sequencing method, and medication guidance, prognosis and efficacy and recurrence monitoring can be performed only by extracting peripheral blood.
A fast and flexible blood ctDNA detection method to accurately quantify tumor-derived DNA for rapid efficacy and recurrence monitoring.
3DMedicines has an international and professional team of talents with both technical and business thinking.
It covers the professional fields of biology, pharmacy, chemistry, bioinformatics, pharmacology, pathology, FDA new drug approval and clinic, and has extensive experience in product development, marketing, business cooperation, drug development and internationalization.